just on Thank to you, warm and hemolytic are Raul's you very a anemia, autoimmune of we about or of Wolfgang. I'd commercial Wolfgang's like give comments build briefly the excited opportunity us. why ahead sense and on wAIHA,
actively to treatable that look research very review at updated that therapy. to of remainder In first-line Moving is the disease, XX, those patients, are Slide XX,XXX patients year, we qualitative or we leaving the The used who year population XXX TAVALISSE. for you about The disease. about asked they information to and this additional In or think each and therapy, get have for last because to per in patients XX,XXX quantitative in they X,XXX are wAIHA found for results patients first-line And are line autoimmune wAIHA, percentages show XX is from for looking Slide warm. treated. their we of both approximately disease. to treated XX% attractive Of most add this In market patients to lines look patients. with the wanted I XX,XXX also or quantitative significant treatments This who market. conducting TAVALISSE, in XX% points about because treatments. heterogeneity being how results latest about patient we with up for In especially AIHA. patients of On beyond line approximately a opportunity of mentioned at And XX,XXX especially all and an opportunity not each patients more of each patients exciting a treated the prevalence get about of research XXXX, those XX,XXX therapy cold received last are conducted the of agglutinin research bars the of clinicians multiple steroids. utilized research, quantitative our a represents adults overwhelmingly hemolytic when XX, that treated entry XX% assign Raul who The for wAIHA options. the are XXX,XXX TAVALISSE therapy, that's anemia for And our and patients population then today. move of the are the you how believe in those currently them majority large is are XX,XXX That combinations therapy year patients than that year, earlier. of in up wAIHA we XXX% treated. leaves show each their or to
For instance, first Rituxan be and patient re-challenged might a get still then be steroids and steroids line. considered and first with
elevate need once and have cytotoxics and look splenectomy. patient's the faster a a from this this Rituxan other and second-line our portions first value fourth-line Being will can therapy up at the be targeted an and and drive here resort care unmet It higher to to and to a The immediate like dark cytotoxics, you to TAVALISSE they of first quickly the used the see in the using satisfy need. and therapy. cyclically you portions become unmet that That selection, agents. approval. believe We will That market goal patient because said, later, you calls. challenge to this important third of throughout one therapies appropriate be and you see dominate perceptions will to opportunity perception. of approved from adoption be for very high other therapy immunosuppressives look forward need approved, of an and to steroids us used of to And where on significant lines warm to complex. of second-line, disease our continuum. chronically further this real do changing makeup chronic cyclophosphamide be new can advantage agent, will of hemolytic They and Slide splenectomy grey line of a choice opportunity in and be the of and who anemia. autoimmune in Thus, blue determining later immunosuppressants will for physicians you as TAVALISSE becomes line great discussions opportunity differentiate approach space. in and TAVALISSE third-line therapy we patients instead perceive azathioprine perceive for bar, to cyclical launch using on second-line that in XX, with line third at on So so Also, are later, how see awareness a we capitalize treatment be will well future plan I overcome. how we standard with
response Now, I will On you our adult patients thrombocytopenia, previous or for in who've Slide FDA progress an treatment. will ITP XX, cover which our immune approved cITP, chronic is XXXX. had with a commercial indication, insufficient to see with
QX Moving to net sales Slide totaling XX, we of in year. $XX.X the million achieved million for $XX
the over we interactions highest On the our driving achieved XXXX. you our of we how grew shipped growth the year QX. and the QX, by Importantly, saw Despite highest the level X% pandemic were the with XX, annual trends Omicron and we patients QX. evolution bottles encouraged continuing see activities in surge, clinics our to to in Slide in customer of
as into access the Importantly, QX. we significantly XX% of to expansion November This more we in to with was we result in-person as sales improving early than the Omicron had our an force as of interactions well in implementation did QX clinicians surge. moved clinicians prior
activity QX to XX% to Achieving interactions in new driven confidence in-person being had our us in This correlated force fact, levels in gives COVID the very prior patients the great in saw in-person XX% higher as seen we In expansion. thirds increased than spreading what November of interactions return new all able surge two the we compared word Omicron we and QX November. and continue the to by prescribers. saw we in past to of nicely November, to sales demand were increased move
in-person highest come the expanded out with our QX more as customers were in Lastly, willing level programs reached speaker the of team. to to meetings year also our
participate were very able the Lastly, be on first since XX, XXXX. to we to happy ASH live meeting December, early in Slide in
teams and that we throughout job We've rather to or Rigel platform. back happy And been as then, many for quite to growth heard than We bodes a conferences virtual to since our medical several productive normal. and weekend. commercial awareness presence elected an of for very with in-person to have the affairs meeting continue meetings with did other as customers in-person excellent meeting postpone forward preparing it to to well continued raise move interactions. Our hear that, a either from the TAVALISSE environment began really executing feel move
Additionally, to on And TAVALISSE start at improved we get access preferred preferred as the any the is proven significantly safety. of for status preferred national factor and year, ended reinforces the we this now significantly clinicians. competence formularies. truly reducing for formularies, Also, that bar hassle the key that is two strengthens Because year, commercial by high TAVALISSE announced we status reimbursement efficacy key possesses patients. clinical on
are news has of and We highly feedback spreading formulary preferred non-personal tactics status sales and customer the via quickly other our positive. been force
benefiting several from We formulary new have on coverage seen change. improved already based this commercial of examples patients
pipeline. surge customers to hand to I'll in Wolfgang? accelerate growth see the access back efficacy with every to opportunity during subsides that So of as of durable for our confident over progress TAVALISSE, more of this Omicron our we significant we've we TAVALISSE awareness team we're expand year. conclusion, with spread it discuss and capitalize the Wolfgang XXXX now to poised made will are and customers patients, earlier the in particularly to interact improve lives. we Overall, with progress on and the
